Cancer Immunotherapy

The Next Great Advance in Cancer Treatment is Here

Cancer immunotherapy—treatments that harness and enhance the innate powers of the immune system to fight cancer—represents the most promising new cancer treatment approach since the development of the first chemotherapies in the late 1940s.

Because of the immune system’s extraordinary power, its capacity for memory, its exquisite specificity, and its central and universal role in human biology, these treatments have the potential to achieve complete, long-lasting remissions and cancer cures, with few or no side effects, and for any cancer patient, regardless of their cancer type.

For 60 years, Cancer Research Institute (CRI) has been the pioneer in advancing this highly promising new class of treatment. Because of this investment, cancer immunotherapy today is a highly active and exciting field, with unprecedented potential to deliver on the decades-long promise of discovering, developing, and delivering safe and effective treatments that make a meaningful difference in the lives of patients fighting the disease.

  • What is Cancer Immunotherapy?

    Immunotherapy is an entirely new class of cancer treatment, with unique characteristics that differentiate it from other kinds of cancer therapies. Go here to learn more about cancer immunotherapy and some of the most promising immunotherapy approaches today.

    Learn More
  • Impacting All Cancers

    Immunotherapy impacting all cancers

    Immunotherapy stands to revolutionize the treatment of almost every kind of cancer. Go here to learn about why immune-based treatments are so promising for many cancer types and how they are impacting cancer treatment today.

    Learn More
  • Clinical Trials

    Find a clinical trial

    Clinical trials are necessary to bring new and potentially life-saving treatments to patients, and may represent the greatest hope for patients currently facing cancer. Go here to learn more about cancer immunotherapy clinical trials and what to consider about enrolling.

    Learn More

More Resources

    Visit our new website for patients and caregivers who are interested in learning more about cancer immunotherapy as a treatment option.
    Visit CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
    CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types. - See more at:
  • Inspire Cancer Immunotherapy Support Community
    Cancer Immunotherapy Support Community
    A new peer-to-peer online group for patients and caregivers on
  • What Cancer Patients Should Know: Latest Immunotherapy News from ASCO
    At the 2015 ASCO annual meeting, CRI scientists discussed the latest immunotherapy breakthroughs and what they mean for patients.
  • 5 Ways to Stop Cancer
    A series of 1-minute animated videos provide a quick overview of the five most common immunotherapies in use.
  • Cancer and the Immune System

    An in-depth look at how the immune system responds to cancer, and how cancer immunologists are using their knowledge about the immune system to develop new ways to conquer cancer. This e-publication contains easy-to-understand graphics and animations to help explain the intricate relationship between cancer and the immune system.

  • CRI Helpbook
    The CRI Helpbook For Patients
    Guide to understanding and coping with cancer, including making treatment decisions and locating sources of support, such as financial assistance, nursing care, equipment, and transportation.


CRI's Cancer Immunotherapy and You Webinar Series is a free, public service that provides information about exciting and revolutionizing developments in cancer immunotherapy research. Meet our scientists and learn more about what they're doing to conquer cancer.

information to the public about exciting breakthroughs and coming developments in cancer immunotherapy. - See more at:

Learn More